Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Entera Bio Ltd (ENTX)

Entera Bio Ltd (ENTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,864
  • Shares Outstanding, K 35,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,890 K
  • 60-Month Beta 1.57
  • Price/Sales 1,229.57
  • Price/Cash Flow N/A
  • Price/Book 8.35
Trade ENTX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 81.41%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,314.84% on 01/17/24
  • IV Low 0.00% on 09/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 387
  • Open Int (30-Day) 349

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.61 +30.43%
on 08/29/24
2.17 -3.23%
on 09/17/24
+0.47 (+28.83%)
since 08/16/24
3-Month
1.41 +48.94%
on 08/05/24
2.18 -3.67%
on 06/21/24
-0.01 (-0.47%)
since 06/18/24
52-Week
0.52 +303.85%
on 12/29/23
3.35 -37.31%
on 04/12/24
+1.44 (+218.18%)
since 09/18/23

Most Recent Stories

More News
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

ENTX : 2.10 (-0.94%)
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

ENTX : 2.10 (-0.94%)
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic...

ENTX : 2.10 (-0.94%)
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and...

ENTX : 2.10 (-0.94%)
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is...

ENTX : 2.10 (-0.94%)
Entera Bio Reports Financial Results for the Year Ended December 31, 2021

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral...

ENTX : 2.10 (-0.94%)
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule...

ENTX : 2.10 (-0.94%)
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒...

ENTX : 2.10 (-0.94%)
Entera Bio Reports Third Quarter 2021 Financial Results

‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3...

ENTX : 2.10 (-0.94%)
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs

‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is...

ENTX : 2.10 (-0.94%)

Business Summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an...

See More

Key Turning Points

3rd Resistance Point 2.35
2nd Resistance Point 2.26
1st Resistance Point 2.19
Last Price 2.10
1st Support Level 2.03
2nd Support Level 1.94
3rd Support Level 1.87

See More

52-Week High 3.35
Fibonacci 61.8% 2.27
Last Price 2.10
Fibonacci 50% 1.93
Fibonacci 38.2% 1.60
52-Week Low 0.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar